Table 2.
Indications for induction among nulliparous women undergoing IOL at term.
| Indication* | Cesarean delivery N=231 |
Vaginal delivery N=554 |
|---|---|---|
| Nonmedically indicated | 9 (3.9) | 19 (3.4) |
| Late-term (<41 weeks of gestation) | 1 (11.1) | 1 (5.3) |
| Diabetes mellitus† | 2 (22.2) | 0 |
| Elective | 6 (66.7) | 17 (89.5) |
| Other | 0 | 1 (5.3) |
| Medically indicated | 222 (96.1) | 535 (96.6) |
| Late-term (≥41 weeks of gestation) | 82 (36.9) | 194 (36.3) |
| PROM | 30 (13.5) | 107 (20.0) |
| Gestational hypertension | 28 (12.6) | 49 (9.2) |
| Preeclampsia/HELLP | 15 (6.8) | 32 (6.0) |
| Diabetes mellitus | 20 (9.0) | 26 (4.9) |
| Chronic hypertension | 6 (2.7) | 8 (1.5) |
| Cholestasis | 1 (0.5) | 6 (1.1) |
| Psychosocial | 1 (0.5) | 3 (0.6) |
| Other | 10 (4.5) | 25 (4.7) |
| Fetal indication | 29 (13.1) | 85 (15.9) |
| Oligohydramnios | 19/29 (65.5) | 43/85 (50.6) |
| FGR | 5/29 (17.2) | 22/85 (25.9) |
| Non-reassuring antenatal testing (NST, BPP, etc.) | 4/29 (13.8) | 12/85 (14.1) |
| Anomalies | 0 | 8/85 (9.4) |
| Other | 1/29 (3.4) | 0 |
Abbreviations: NST, non-stress test; BPP, biophysical profile; HELLP, hemolysis, elevated liver enzyme levels, and low platelet levels; FGR, fetal growth restriction; PROM, premature rupture of membranes.
*
Type of indication (nonmedically indicated compared to medically indicated) was not significantly associated with cesarean delivery (p=0.75).
†
Diabetes indication deemed nonmedically indicated depending on pregestational or gestational and control and/or comorbidities.